Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IPI Legacy Liquidation CoIMPL · Entity 15659 | CFO | May 10, 2023 | May 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IPI Legacy Liquidation Co
Report date May 10, 2023 · Filed May 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2033-05-10 | Direct | 175,000 |
Reported balance
After 2023-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-10 · Grant · Acquired 175,000 · Balance 175,000 F1: The option vests as to 25% of the total shares on May 10, 2024 and then 1/48th of the total shares vests on each monthly anniversary thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Expires 2033-05-10 | Direct | 47,500 |
Reported balance
After 2023-05-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-10 · Grant · Acquired 47,500 · Balance 47,500 F2: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3: The RSUs vest as to 100% of the total shares on May 31, 2024, subject to the reporting person's continuation of employment on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the total shares on May 10, 2024 and then 1/48th of the total shares vests on each monthly anniversary thereafter, subject to the reporting person's provision of service to the issuer on each vesting date.
F2: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F3: The RSUs vest as to 100% of the total shares on May 31, 2024, subject to the reporting person's continuation of employment on such vesting date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMARIN CORP PLC\UK
Report date July 29, 2022 · Filed August 03, 2022
Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 301,882 |
Reported balance
After 2022-07-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-07-29 · Exercise / conversion · Acquired 47,767 · Balance 301,882 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: On August 2, 2021, the Reporting Person was granted 143,300 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). These RSUs vest in three equal installments on each of July 31, 2022, July 31, 2023 and July 31, 2024. As the first vesting date fell on a weekend, the first vesting event occurred on July 29, 2022, the previous business day. F3: Not applicable. F4: Includes 3,368 shares purchased under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2022. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 284,662 |
Reported balance
After 2022-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-07-29 · Tax withholding · Disposed 17,220 · Balance 284,662 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 337,314 |
Reported balance
After 2022-08-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-08-01 · Tax withholding · Disposed 29,682 · Balance 337,314 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F6: Reflects the effect of certain non-reportable transactions occurring following the Reporting Person's separation of service with the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 95,533 |
Reported balance
After 2022-07-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-29 · Exercise / conversion · Disposed 47,767 · Balance 95,533 F7: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: On August 2, 2021, the Reporting Person was granted 143,300 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). These RSUs vest in three equal installments on each of July 31, 2022, July 31, 2023 and July 31, 2024. As the first vesting date fell on a weekend, the first vesting event occurred on July 29, 2022, the previous business day. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: On August 2, 2021, the Reporting Person was granted 143,300 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). These RSUs vest in three equal installments on each of July 31, 2022, July 31, 2023 and July 31, 2024. As the first vesting date fell on a weekend, the first vesting event occurred on July 29, 2022, the previous business day.
F3: Not applicable.
F4: Includes 3,368 shares purchased under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2022.
F5: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
F6: Reflects the effect of certain non-reportable transactions occurring following the Reporting Person's separation of service with the Issuer.
F7: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
CATALYST PHARMACEUTICALS, INC.
Report date July 15, 2026 · Filed July 17, 2026
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Disposition to issuer · Disposed 13,665 · Balance 0 F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-01-01 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 257,214 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.12 · Expires 2031-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 169,248 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $22.77 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Disposition to issuer · Disposed 131,536 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 21,416 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F5: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 13,788 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F5: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 39,701 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F5: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F5: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
CinCor Pharma, Inc.
Report date February 24, 2023 · Filed February 24, 2023
Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 1
1 source rowRow 1 · 2023-02-24 · Disposition to issuer · Disposed 202,437 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: This line item represents restricted stock units ("RSUs") held by the Reporting Person at the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each outstanding RSU was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to (a) the total number of Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (b) $26.00 per share (the "Cash Amount"), and (ii) one contingent value right ("CVR") per Share issuable in settlement of such RSU, representing the right to receive a contingent payment of $10.00 per share (the "Milestone Payment"), in cash, upon the achievement of a specified milestone by December 31, 2033. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.07 · Expires 2032-11-03 | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-24 · Disposition to issuer · Disposed 77,615 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than the Cash Amount was accelerated and became fully vested and exercisable and automatically converted into the right to receive, upon the occurrence of the Milestone Payment Date (as defined in the CVR Agreement), an amount in cash equal to the product of (a) the total number of Shares subject to such option immediately prior to the effective time of the merger multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the Milestone Payment exceeds (2) the exercise price payable per Share under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: This line item represents restricted stock units ("RSUs") held by the Reporting Person at the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each outstanding RSU was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to (a) the total number of Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (b) $26.00 per share (the "Cash Amount"), and (ii) one contingent value right ("CVR") per Share issuable in settlement of such RSU, representing the right to receive a contingent payment of $10.00 per share (the "Milestone Payment"), in cash, upon the achievement of a specified milestone by December 31, 2033.
F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than the Cash Amount was accelerated and became fully vested and exercisable and automatically converted into the right to receive, upon the occurrence of the Milestone Payment Date (as defined in the CVR Agreement), an amount in cash equal to the product of (a) the total number of Shares subject to such option immediately prior to the effective time of the merger multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the Milestone Payment exceeds (2) the exercise price payable per Share under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 39,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000178 · form_4.xml · derivative · entry 7 Kalb Michael Wayne · CIK 0001678248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,701 shares Expires 2028-11-20 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F5 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 13,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000178 · form_4.xml · derivative · entry 6 Kalb Michael Wayne · CIK 0001678248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,788 shares Expires 2027-11-21 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F5 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 21,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000178 · form_4.xml · derivative · entry 5 Kalb Michael Wayne · CIK 0001678248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,416 shares Expires 2029-01-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F5 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 131,536 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-26-000178 · form_4.xml · derivative · entry 4 Kalb Michael Wayne · CIK 0001678248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,536 shares Expires 2032-11-20 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 169,248 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001161697-26-000178 · form_4.xml · derivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,248 shares Expires 2031-11-21 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 257,214 | $0.00 Strike: $16.81 | $0.00 |
DisclosureSEC source: 0001161697-26-000178 · form_4.xml · derivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257,214 shares Expires 2031-01-01 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerCommon Stock, par value $0.001 per share | 13,665 | $31.50 | $430,447.50 |
DisclosureSEC source: 0001161697-26-000178 · form_4.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 7,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000022 · form_4.xml · derivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,903 Underlying: Common Stock · 7,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 2,080 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-26-000022 · form_4.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,665 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 7,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-26-000022 · form_4.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 6,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000418 · form_4.xml · derivative · entry 5 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640,042 Underlying: Common Stock · 6,894 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of common stock will be delivered to the Reporting Person upon vesting. F5 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027. F6 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 2,485 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000418 · form_4.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,606 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 6,894 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000418 · form_4.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 39,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000418 · form_4.xml · derivative · entry 4 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,936 Underlying: Common Stock · 39,701 shares Expires not disclosed F4 · derivative.exercise_price: Shares of common stock will be delivered to the Reporting Person upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. F4 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 131,536 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-25-000418 · form_4.xml · derivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 607,235 Underlying: Common Stock · 131,536 shares Expires 2032-11-20 F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 7,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000026 · form_4.xml · derivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,699 Underlying: Common Stock · 7,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/5th each on January 1, 2025, 2026, 2027, 2028 and 2029. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on January 2, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 2,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000026 · form_4.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,197 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 7,138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000026 · form_4.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 20,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000478 · form_4.xml · derivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,837 Underlying: Common Stock · 20,682 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026 and 1/3rd on November 21, 2027. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 169,248 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001161697-24-000478 · form_4.xml · derivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,155 Underlying: Common Stock · 169,248 shares Expires 2031-11-21 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026 and 1/3rd on November 21, 2027. Read SEC document |
| May 10, 2023 Filed May 12, 2023 16:41 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantRestricted Stock Units (RSUs) · Derivative | 47,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029076 · doc4.xml · derivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2033-05-10 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 100% of the total shares on May 31, 2024, subject to the reporting person's continuation of employment on such vesting date. Read SEC document |
| May 10, 2023 Filed May 12, 2023 16:41 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001209191-23-029076 · doc4.xml · derivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-05-10 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on May 10, 2024 and then 1/48th of the total shares vests on each monthly anniversary thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 24, 2023 Filed Feb 24, 2023 23:38 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | Disposition to issuerStock Option (Right to Buy) · Derivative | 77,615 | Not disclosed Strike: $30.07 | Not disclosed |
DisclosureSEC source: 0001209191-23-012895 · doc4.xml · derivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,615 shares Expires 2032-11-03 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than the Cash Amount was accelerated and became fully vested and exercisable and automatically converted into the right to receive, upon the occurrence of the Milestone Payment Date (as defined in the CVR Agreement), an amount in cash equal to the product of (a) the total number of Shares subject to such option immediately prior to the effective time of the merger multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the Milestone Payment exceeds (2) the exercise price payable per Share under such option. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than the Cash Amount was accelerated and became fully vested and exercisable and automatically converted into the right to receive, upon the occurrence of the Milestone Payment Date (as defined in the CVR Agreement), an amount in cash equal to the product of (a) the total number of Shares subject to such option immediately prior to the effective time of the merger multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the Milestone Payment exceeds (2) the exercise price payable per Share under such option. Read SEC document |
| February 24, 2023 Filed Feb 24, 2023 23:38 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | Disposition to issuerCommon Stock | 202,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-012895 · doc4.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2 · shares: This line item represents restricted stock units ("RSUs") held by the Reporting Person at the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each outstanding RSU was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to (a) the total number of Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (b) $26.00 per share (the "Cash Amount"), and (ii) one contingent value right ("CVR") per Share issuable in settlement of such RSU, representing the right to receive a contingent payment of $10.00 per share (the "Milestone Payment"), in cash, upon the achievement of a specified milestone by December 31, 2033. F2 · price: This line item represents restricted stock units ("RSUs") held by the Reporting Person at the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each outstanding RSU was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to (a) the total number of Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (b) $26.00 per share (the "Cash Amount"), and (ii) one contingent value right ("CVR") per Share issuable in settlement of such RSU, representing the right to receive a contingent payment of $10.00 per share (the "Milestone Payment"), in cash, upon the achievement of a specified milestone by December 31, 2033. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 01:04 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | GrantCommon Stock | 177,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-005590 · doc4.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,437 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date. F1 · price: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 22:08 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,615 | $0.00 Strike: $30.07 | $0.00 |
DisclosureSEC source: 0001209191-22-056126 · doc4.xml · derivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,615 Underlying: Common Stock · 77,615 shares Expires 2032-11-03 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on November 4, 2023, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 22:08 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | GrantCommon Stock | 25,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056126 · doc4.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,437 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-half (1/2) of the RSUs shall vest on November 4, 2024 and the remaining RSUs shall vest in two (2) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. F1 · price: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-half (1/2) of the RSUs shall vest on November 4, 2024 and the remaining RSUs shall vest in two (2) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 00:07 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingOrdinary Shares | 29,682 | $1.33 | $39,477.06 |
DisclosureSEC source: 0001562180-22-005838 · primarydocument.xml · nonDerivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,314 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F6 · balance_after: Reflects the effect of certain non-reportable transactions occurring following the Reporting Person's separation of service with the Issuer. Read SEC document |
| July 29, 2022 Filed Aug 3, 2022 00:07 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Units · Derivative | 47,767 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005838 · primarydocument.xml · derivative · entry 4 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,533 Underlying: Ordinary Shares · 47,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: On August 2, 2021, the Reporting Person was granted 143,300 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). These RSUs vest in three equal installments on each of July 31, 2022, July 31, 2023 and July 31, 2024. As the first vesting date fell on a weekend, the first vesting event occurred on July 29, 2022, the previous business day. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 29, 2022 Filed Aug 3, 2022 00:07 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingOrdinary Shares | 17,220 | $1.33 | $22,902.60 |
DisclosureSEC source: 0001562180-22-005838 · primarydocument.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,662 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. Read SEC document |
| July 29, 2022 Filed Aug 3, 2022 00:07 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 47,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-005838 · primarydocument.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: On August 2, 2021, the Reporting Person was granted 143,300 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). These RSUs vest in three equal installments on each of July 31, 2022, July 31, 2023 and July 31, 2024. As the first vesting date fell on a weekend, the first vesting event occurred on July 29, 2022, the previous business day. F3 · price: Not applicable. F4 · balance_after: Includes 3,368 shares purchased under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Units · Derivative | 16,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002153 · primarydocument.xml · derivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,333 Underlying: Ordinary Shares · 16,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: On March 2, 2020, the Reporting Person was granted 49,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan. These RSUs vest in three equal installments on each of February 28, 2021, February 28, 2022 and February 28, 2023. The second vesting event occurred on February 28, 2022. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingOrdinary Shares | 6,213 | $3.27 | $20,316.51 |
DisclosureSEC source: 0001562180-22-002153 · primarydocument.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,747 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 16,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-002153 · primarydocument.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: On March 2, 2020, the Reporting Person was granted 49,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan. These RSUs vest in three equal installments on each of February 28, 2021, February 28, 2022 and February 28, 2023. The second vesting event occurred on February 28, 2022. F3 · price: Not applicable. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 01:05 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 103,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001247 · primarydocument.xml · derivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,700 Underlying: Ordinary Shares · 103,700 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F4 · derivative.exercise_date: On February 4, 2022, the Reporting Person was granted 103,700 RSUs under the 2020 Plan. These RSUs vest in three equal installments on each of January 31, 2023, January 31, 2024 and January 31, 2025. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 01:05 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 131,700 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001562180-22-001247 · primarydocument.xml · derivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,700 Underlying: Ordinary Shares · 131,700 shares Expires 2032-02-04 F1 · derivative.exercise_date: On February 4, 2022, the Reporting Person was granted an option to purchase 131,700 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each April, July, October and January. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Units · Derivative | 12,733 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000983 · primarydocument.xml · derivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: On February 1, 2019, the Reporting Person was granted 38,200 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021 and January 31, 2022. The third and final vesting event occurred on January 31, 2022. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingOrdinary Shares | 5,317 | $3.36 | $17,865.12 |
DisclosureSEC source: 0001562180-22-000983 · primarydocument.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,627 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 12,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-000983 · primarydocument.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: On February 1, 2019, the Reporting Person was granted 38,200 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021 and January 31, 2022. The third and final vesting event occurred on January 31, 2022. F3 · price: Not applicable. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:08 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Units · Derivative | 47,767 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000171 · primarydocument.xml · derivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,533 Underlying: Ordinary Shares · 47,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: On January 4, 2021, the Reporting Person was granted 143,300 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). These RSUs vest in three equal installments on each of December 31, 2021, December 31, 2022 and December 31, 2023. The first vesting event occurred on December 31, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:08 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingOrdinary Shares | 25,379 | $3.35 | $85,019.65 |
DisclosureSEC source: 0001562180-22-000171 · primarydocument.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,211 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F6 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:08 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 47,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-000171 · primarydocument.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: On January 4, 2021, the Reporting Person was granted 143,300 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). These RSUs vest in three equal installments on each of December 31, 2021, December 31, 2022 and December 31, 2023. The first vesting event occurred on December 31, 2021. F3 · price: Not applicable. F4 · balance_after: Includes 2,716 shares purchased under the Issuer's 2017 Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Units · Derivative | 3,054 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-005782 · primarydocument.xml · derivative · entry 7 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,054 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vested ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-sixth and final vesting event occurred on August 31, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Units · Derivative | 1,527 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-005782 · primarydocument.xml · derivative · entry 6 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vested ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-sixth and final vesting event occurred on August 31, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Units · Derivative | 1,527 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-005782 · primarydocument.xml · derivative · entry 5 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vested ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-sixth and final vesting event occurred on August 31, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingOrdinary Shares | 3,011 | $5.54 | $16,680.94 |
DisclosureSEC source: 0001562180-21-005782 · primarydocument.xml · nonDerivative · entry 4 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,107 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 3,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-005782 · primarydocument.xml · nonDerivative · entry 3 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vested ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-sixth and final vesting event occurred on August 31, 2021. F3 · price: Not applicable. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 1,527 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-005782 · primarydocument.xml · nonDerivative · entry 2 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vested ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-sixth and final vesting event occurred on August 31, 2021. F3 · price: Not applicable. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionOrdinary Shares | 1,527 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-005782 · primarydocument.xml · nonDerivative · entry 1 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vested ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-sixth and final vesting event occurred on August 31, 2021. F3 · price: Not applicable. Read SEC document |
| August 12, 2021 Filed Aug 14, 2021 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001562180-21-005317 · primarydocument.xml · derivative · entry 5 Kalb Michael Wayne · CIK 0001678248 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Ordinary Shares · 25,000 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 1, 2017, the Reporting Person was granted an option to purchase 133,000 Ordinary Shares under the Plan. The shares subject to this option vested and became exercisable in 48 equal monthly installments on the last day of each month starting on February 28, 2017. This option was fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.